Neostigmine methylsulfate NDC 71839-106

NDC codes

FDA NDC Directory

Product NDC (as listed)71839-106Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71839-0106Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71839-106-10	71839010610	10 VIAL, MULTI-DOSE in 1 CARTON (71839-106-10) / 10 mL in 1 VIAL, MULTI-DOSEMarketed from Mar 17, 2022
71839-106-24	71839010624	24 CARTON in 1 CARTON (71839-106-24) / 1 VIAL, MULTI-DOSE in 1 CARTON (71839-106-01) / 10 mL in 1 VIAL, MULTI-DOSEMarketed from May 13, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Neostigmine methylsulfate
Generic name (nonproprietary): neostigmine methylsulfate
Active ingredients: Neostigmine methylsulfate — 1 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: BE Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212512
Marketing start: May 13, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Cholinesterase Inhibitors (Mechanism)
Identifiers: Product ID 71839-106_a90a9fa9-dc93-4e87-94fa-e578918ccfceSPL ID a90a9fa9-dc93-4e87-94fa-e578918ccfceSPL set ID 971713db-d5ac-44c1-ada5-a56a943d79bfRxCUI 311935, 311936UNII 98IMH7M386UPC 0371839106011, 0371839105014
Pharmacologic class: Cholinesterase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N471839010610 followed by a unit qualifier and the quantity

Package 71839-0106-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 18, 2022.

Indications (excerpt from the label)

Neostigmine methylsulfate injection is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery ( 1 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212512

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212512
Product	Strength	Form · route	Labeler	Product NDC
Neostigmine methylsulfate	Neostigmine methylsulfate .5 mg/mL	InjectionIntravenous	BE Pharmaceuticals Inc.	71839-105
neostigmine methylsulfate	Neostigmine methylsulfate .5 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-994
neostigmine methylsulfate	Neostigmine methylsulfate 1 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-995